Nivolumab, a human
monoclonal antibody against programmed death-1, is approved for the treatment of
non-small cell lung cancer (NSCLC). Although
nivolumab is generally well tolerated, it can cause
interstitial lung disease (ILD), a rare but potentially fatal immune-related adverse event. Currently, there are limited data available on the treatment of
nivolumab-induced ILD and its outcome. This retrospective cohort study based on a post-marketing study described the treatment of
nivolumab-induced ILD and its outcome in NSCLC patients in Japan through the assessment of clinical and chest imaging findings by an expert central review committee. Treatment details for patients who experienced a relapse of ILD were also analyzed. Of the 238 patients identified as having
nivolumab-induced ILD, 37 patients died of ILD.
Corticosteroids were used in 207 (87.0%) patients. Of those, 172 (83.1%) patients responded well and survived and 35 (16.9%) died (most died during
corticosteroid treatment). A total of nine patients experienced a relapse; at the time of relapse, four patients were taking
nivolumab. Of those who were receiving
corticosteroids at the time of relapse, three of four patients were taking low doses or had nearly completed
dose tapering. All patients (except one, whose treatment was unknown) received
corticosteroids for the treatment of relapse, but one patient died. Patients with NSCLC who experience
nivolumab-induced ILD are treated effectively with
corticosteroids, and providing extra care when ceasing or reducing the
corticosteroid dose may prevent relapse of ILD.